Wells Fargo & Company MN trimmed its holdings in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 24.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 277,977 shares of the specialty pharmaceutical company’s stock after selling 92,033 shares during the quarter. Wells Fargo & Company MN owned 0.53% of Supernus Pharmaceuticals worth $9,198,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Municipal Employees Retirement System of Michigan increased its holdings in Supernus Pharmaceuticals by 2.2% in the second quarter. Municipal Employees Retirement System of Michigan now owns 15,650 shares of the specialty pharmaceutical company’s stock valued at $518,000 after buying an additional 330 shares during the last quarter. Bridge City Capital LLC lifted its position in Supernus Pharmaceuticals by 0.5% in the second quarter. Bridge City Capital LLC now owns 69,000 shares of the specialty pharmaceutical company’s stock worth $2,283,000 after purchasing an additional 338 shares during the period. Oregon Public Employees Retirement Fund lifted its position in Supernus Pharmaceuticals by 1.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock worth $709,000 after purchasing an additional 366 shares during the period. Baltimore Washington Financial Advisors Inc. lifted its position in shares of Supernus Pharmaceuticals by 0.9% during the 2nd quarter. Baltimore Washington Financial Advisors Inc. now owns 45,033 shares of the specialty pharmaceutical company’s stock valued at $1,490,000 after acquiring an additional 420 shares during the last quarter. Finally, Diversified Trust Co lifted its position in shares of Supernus Pharmaceuticals by 8.4% during the 2nd quarter. Diversified Trust Co now owns 6,450 shares of the specialty pharmaceutical company’s stock valued at $213,000 after acquiring an additional 500 shares during the last quarter. 99.35% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Jack A. Khattar acquired 7,200 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was acquired at an average cost of $26.39 per share, for a total transaction of $190,008.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 6.57% of the company’s stock.
Several brokerages have issued reports on SUPN. TheStreet downgraded shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Thursday, August 29th. Mizuho reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, August 7th. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group set a $46.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. Finally, Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $53.38.
Shares of Supernus Pharmaceuticals stock traded down $0.13 during trading on Friday, hitting $27.76. 3,422 shares of the stock were exchanged, compared to its average volume of 484,017. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 13.53, a price-to-earnings-growth ratio of 0.98 and a beta of 1.62. The company has a fifty day moving average price of $28.86 and a 200-day moving average price of $33.29. Supernus Pharmaceuticals Inc has a 1-year low of $25.32 and a 1-year high of $51.38. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.56 by $0.05. The business had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. Supernus Pharmaceuticals’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.57 EPS. Equities research analysts forecast that Supernus Pharmaceuticals Inc will post 2.16 EPS for the current fiscal year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Story: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.